BIOCON Charts, Analysis and Tips

home > pharma-and-healthcare > pharmaceuticals > biocon

Technical Analysis

Technical Strength: 7.5 / 10
Indicator Analysis Signal (0 - 10) Chart
RSI (?) RSI is 61.5. According to RSI analysis, biocon is strong. 7.0 BIOCON RSI Chart
MACD (?) MACD: 9.17 and Signal Line: 5.75. According to MACD analysis, biocon is technically strong. 8.0 BIOCON MACD Chart
Simple Moving Average (?) According to simple moving average analysis, biocon is in a uptrend. Support level is at 356. 9.0 BIOCON Simple Moving Average Chart
Exponential Moving Average (?) According to exponential moving average analysis, biocon is in a strong uptrend. Major support levels are 361.3551, 354.0331, 340.1617. 10.0 BIOCON Exponential Moving Average Chart
Bollinger Bands (?) %b is 0.786. According to bollinger bands, biocon is technically strong. 7.0 BIOCON Bollinger Bands Chart
Fibonacci Retracement (?) According to fibonacci retracement, price is above all levels. Major support is at 365.389 and 358.25. Resistance level is 388.5. 6.5 BIOCON Fibonacci Retracement Chart
Average True Range (?) ATR: 11.3 NA BIOCON Average True Range Chart
Average Directional Index (?) ADX is 24.6 which means BIOCON is in a trading range and there is no trend. NA BIOCON Average Directional Index Chart
Note: Technical Analysis updated at 7PM on every trading day.
End-of-Day Share Price - NSE
October 19, 2017
Open Price 383.0
High Price 386.2
Low Price 373.25
Close Price 376.25
Absolute Change -5.8
Percentage Change -1.52%
Weekly Change 1.18%
Monthly Change 6.06%
Yearly Change 19.1%
52-week high 438.85
52-week low 268.133333333
Corporate Actions
ExDate Purpose
July 20, 2017 AGM/DIV-RE 1 PER SHARE
June 15, 2017 BONUS 2:1
June 22, 2016 ANNUAL GENERAL MEETING
See all Corporate Actions
Volume Chart
Real time prices can be delayed by 20 minutes. Prices are refreshed from our server automatically after 1 minute. If NSE real time price is not available then BSE real time prices are provided. Volume displayed might not be correct..

Fundamental Analysis

Beta (?)0.758
Confidence in Beta5.39%
Market Capital Rs. 7524.0 Cr
Diluted Trailing Twelve Months (TTM) Earnings Per Share (EPS) Rs. 14.5566666667
TTM Price-to-Earnings (P/E) Ratio 25.8
Whenever available, consolidated financial results are used. For details, see here.
Stock Deliverable Quantity and Daily Volatility
Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
Deliverable Quantity (?) 19 October 2017: Deliverable Quantity:1.19e+05 NA BIOCON Deliverable Quantity Chart
Annualized Daily Volatility (Spot Price) (?) 19 October 2017: Daily Volatility:0.4241 NA BIOCON Annualized Daily Volatility (Spot Price) Chart

Futures & Options Analysis

Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
PCR (?) 19 October 2017: PCR_OI:0.713 PCR:0.5 NA BIOCON PCR Chart
Option Pain (?) 19 October 2017: Max Pain:370.0 NA BIOCON Option Pain Chart
Premium (?) 19 October 2017 Premium: -0.4 Futures OI:9115200.0 NA BIOCON Premium Chart
Option_MAX_OI (?) 19 October 2017: Price:376.25 Put with maximum OI:350.0 Call with maximum OI:400.0 NA BIOCON Option_MAX_OI Chart

Futures - NSE

Expiry Date Close Price Open Interest Number of Trades No of Contracts Underlying Closing Price
October 26, 2017 375.85 9115200.0 486.0 500.0 376.25
November 30, 2017 378.25 1681200.0 43.0 49.0 376.25
December 28, 2017 382.8 9000.0 1.0 1.0 376.25

Announcements

October 10, 2017 BiocPress Releasecon Limited has informed the Exchange regarding a press release dated October 10, 2017, titled "US FDA Issues Complete Response Letter for Proposed Biosimilar Pegfilgrastim ".
September 21, 2017 BiocAnalysts/Institutional Investor Meet/Con. Call Updatescon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates
See all Announcements

Board Meetings

Date Meeting Date Purpose
September 27, 2017 October 26, 2017 InteResultser alia, consider, approve and take on record, the un-audited financial results (both standalone and consolidated) of the Company for the quarter and half year ended September 30, 2017 amongst other routine matters.
June 30, 2017 July 27, 2017 inteResults/Otherser alia, to consider, approve and take on record, the un-audited financial results (both standalone and consolidated) of the Company for the quarter ended June 30, 2017 amongst other routine matters.
See all Board Meetings

BIOCON is part of...

Index Weightage
NFTYMCAP50 NA

Intraday Pivot Points

S3 S2 S1 Pivot R1 R2 R3
Rs. 358 Rs. 365.6 Rs. 370.9 Rs. 378.6 Rs. 383.9 Rs. 391.5 Rs. 396.8